Is Alzheimer's disease, relentless and slow, a better target for clinical trials?

Published Date: 16 Feb 2023

According to a report by the Alzheimer's Association task force, it's time to reframe what "clinically meaningful" means and change expectations about clinical trials.

Read Full News

Latest News



Todays Updates


FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Isabella Ciccone, MPH


TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

NeuroVoices: Richard Rammo, MD, on How Thalamic Neuromodulation is Evolving for Drug Resistant Epilepsy Marco Meglio, Richard Rammo, MD


The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH


A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder Louie Pasculli


A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

Long-Term Expanded Access Program Data Support Phase 3 Development of Bexicaserin in Developmental Epileptic Encephalopathies Marco Meglio


New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.

FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning Isabella Ciccone, MPH


Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Patient Attitudes Key to Effective Hyperuricemia Self-Management


Patient Attitudes Key to Effective Hyperuricemia Self-Management

Todays Updates


FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Isabella Ciccone, MPH


TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

NeuroVoices: Richard Rammo, MD, on How Thalamic Neuromodulation is Evolving for Drug Resistant Epilepsy Marco Meglio, Richard Rammo, MD


The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH


A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder Louie Pasculli


A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

Long-Term Expanded Access Program Data Support Phase 3 Development of Bexicaserin in Developmental Epileptic Encephalopathies Marco Meglio


New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.

FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning Isabella Ciccone, MPH


Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Patient Attitudes Key to Effective Hyperuricemia Self-Management


Patient Attitudes Key to Effective Hyperuricemia Self-Management

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

3D virtual staining technology enables non-invasive observation of cancer tissue

2.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

3.

Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.

4.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

5.

Year in Review: Non-Small Cell Lung Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot